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The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 
Japanese Encephalitis Vaccine Given with a Two-dose Primary 
Schedule in Children 
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis 
(JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has 
been widely used since its introduction, the systemic data of LAJEV was very rarely available 
in Korea. We conducted the open-label, prospective cohort study to assess the 
immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 
2-dose primary series was given with a 12-month interval. Neutralizing antibody titers 
were measured before and after each vaccination, and active monitoring for adverse 
events was performed. After the first dose, 91.1% of subjects had seroprotection with a 
geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, 
and GMT showed an increase of 6.5-fold. Most adverse events following immunization 
were self-limited, and no serious adverse events were reported until 42 days after each 
dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared 
to be highly immunogenic and safe. 
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INTRODUCTION
Japanese encephalitis (JE) virus is the leading cause of viral en-
cephalitis in Asia. The recent emergence of JE virus in new ter-
ritories that has been attributable to the climate change and in-
ternational travel has raised the concern of global public health 
(1, 2). Because there are still limitations in vector control and 
specific antiviral treatment of JE, vaccination is the most effec-
tive strategy for prevention.
 Although the inactivated Vero-cell culture JE vaccine has re-
cently introduced, two JE vaccines have been widely used in 
Korea: the mouse brain-derived, killed-inactivated JE vaccine 
(MBDV) and the live attenuated SA 14-14-2 JE vaccine (LAJEV). 
MBDV was first developed in Japan (BIKEN, distributed by Sano-
fi Pasteur as JE-VAX) and the only commercially used vaccine 
worldwide for past decades (3, 4). Local productions of similar 
vaccine have been used effectively to immunize travelers and 
residents in enzootic areas, and this has reduced JE incidence 
in some countries. However, the MBDV had the uncertainty as 
to the duration of protection and required multiple doses to main-
tain immunity (5, 6). In addition, an unacceptable occurrence 
of neurologic and hypersensitivity reactions has prompted a 
major manufacturer to cease production in Japan (6-8). In 1994, 
two cases of death temporally associated with MBDV led to a 
serious social issue, and to establish the Vaccine Injury Com-
pensation Program in Korea. As such, there has been an appar-
ent need for a vaccine with an enhanced safety profile and small-
er dose schedule to protect against JE, which led to the intro-
duction of LAJEV.
 Since its licensure in 1988, more than 300 million doses of 
LAJEV have been administered in China where it has shown an 
excellent efficacy and safety profile (9, 10). This vaccine manu-
factured in China has been used in countries of western pacific 
region and Asia (Nepal, Sri Lanka, India, and Korea), and con-
stituted more than 50% of the global production of all JE vac-
cines in 2005 (11). However, the lack of precedence for using a 
primary hamster kidney cell line as the substrate and the safety 
profile remain special issues of concern (12). Nevertheless, some 
physicians prefer to use the LAJEV because of simple schedule 
compared with MBDV. The primary series in Korea is sched-
uled with two doses administered 12 months apart in infants 
aged 1-2 yr. This preferred interval was established based only 
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on data from studies conducted in China (13), and no published 
data for the primary series using a 12-month interval exists for 
countries other than China. Therefore, this study was undertak-
en to assess the immunogenicity and safety of LAJEV according 
to the local schedule in Korea. 
MATERIALS AND METHODS
Study design
The study was designed as an open-label, prospective cohort, 
multicenter trial in Korea. The study was performed at five cen-
ters between July 2, 2007 and October 26, 2009. At enrollment, 
eligible participants from 1 to 3 yr of age were given a brief health 
examination, blood samples were taken, and the first vaccine 
dose was administered. A follow-up visit occurred at 4-6 weeks 
after vaccination, at which point blood samples were collected 
from all children. One year after the first vaccination, a blood 
sample was collected and the second vaccine dose was admin-
istered. As with the first dose, a follow-up visit was done at 4-6 
weeks after second vaccination and blood samples for immu-
nogenicity analysis were collected. 
Study subjects
Healthy children without significant medical history or clinically 
significant physical examination or laboratory findings at screen-
ing were eligible. Exclusion criteria included: congenital or ac-
quired immunodeficiency or immunosuppressive conditions; 
hypersensitivity to any of the vaccine components; use of sys-
temic corticosteroids, immunosuppressive medications, or bio-
logical agents in the previous 3 months or anticipated adminis-
tration of such medications during the course of the study; a 
known history of clinically, serologically or microbiologically 
confirmed flavivirus infection; or febrile or acute illness on the 
day of injection. The protocol allowed children to receive addi-
tional vaccines as recommended, including hepatitis A vaccine 
at 12 to 24 months of age, Haemophilus influenzae type b con-
jugate vaccine and pneumococcal conjugate vaccine at 12 to15 
months of age, and diphtheria, tetanus, acellular pertussis (DTaP) 
vaccine at 15 to 18 months of age, as long as doses were given at 
least 8 days after and at least 4 weeks before a dose of the study 
vaccine. Measles, mumps, rubella (MMR) and varicella vaccines 
were allowed if administered at least 4 weeks before or after ad-
ministration of the study vaccine.
Study vaccine
LAJEV (CD-JEVAXTM, Chengdu Institute of Biological Products, 
Chengdu, China) was used in this study. The main component 
of this vaccine is SA14-14-2 strain of JE virus. The others are lac-
tose, sucrose, gelatin, human blood albumin and urea. Each sub-
ject was administered 0.5 mL of freshly reconstituted vaccine sub-
cutaneously to the upper arm as instructed by the manufacturer. 
Immunogenicity evaluation
Blood samples for immunogenicity assays were taken prior to 
and 4-6 weeks after each vaccination. The samples were kept 
frozen at -70°C and were sent to the central laboratory of the 
Korean National Institute of Health. Sera were tested for neu-
tralizing antibodies using the plaque reduction neutralization 
test (PRNT) as followings. Test sera were heat-inactivated at 
56°C for 30 min and diluted 1:5 and in serial two fold dilutions 
(up to 1:2,560). The Nakayama strain (heterologous SA-14-14 
strain) was diluted in phosphate buffer saline containing 5% fe-
tal calf serum and 5% guinea pig complement to provide 200 
pfu/0.1 mL, and added in equal volume to each serum dilution. 
Serum-virus mixtures were incubated over-night at 48°C and 
added to drained baby hamster kidney 21 cell culture monolay-
ers grown in six well plates. After adsorption for one hour at 
37°C, the monolayers were overlaid with semisolid medium. 
Approximately 5 days later, when plaques could be seen micro-
scopically, the medium was removed. The complete titration of 
each serum was carried out in a single test (14). The end point 
for neutralization was the highest dilution of serum reducing 
plaques by 50% of the JE challenge virus, compared with a neg-
ative serum control. JE neutralizing antibody titer ≥ 10 was con-
sidered seropositive and seroprotective (15). 
Safety evaluation 
After vaccination, a physician monitored subjects for any im-
mediate sign or symptom of local and/or systemic reactions for 
at least 30 min. We asked the parents or legal guardians to re-
cord any adverse reactions occurred from days 0-42 after vacci-
nation. Significant local reaction was defined as redness > 2.5 
cm, swelling > 2.5 cm, or tenderness, or crying and protesting 
when the injection site was touched. Systemic reactions includ-
ed vomiting, diarrhea, irritability, drowsiness, loss of appetite, 
shivering, or fever. Fever was defined as a temperature ≥ 38°C 
(100.4°F) (16). Symptoms were defined as being related if there 
was a reasonable possibility that the vaccine contributed to the 
adverse event. Unsolicited local or systemic reactions (with on-
set date, intensity and resolution) were recorded throughout 
the 42-day period after each vaccination. Serious adverse events 
were reported for the duration of the study. Blood pressure, pulse, 
and body temperature of all subjects were recorded at every vis-
it, and physical examinations were performed.
Statistical analysis
Based on the premise of a 98% production rate of seroprotec-
tive antibody, a 10% allowable error for the trial and 10% level 
of significance, the minimum necessary number of subjects 
was found to be 65 in this study. Immunogenic response was 
assessed by the percentage of subjects with seroprotective neu-
tralizing antibody titer and by calculation of the geometric mean 
titer (GMT) values. For the GMT, 95% confidence intervals (CI) 
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Table 1. Neutralizing antibody responses determined by PRNT50 before and after each vaccination
Dose                Antibody responses Pre-vaccination Post-vaccination
Dose 1 Seropositive rate (%) 10/90 (11.1) 82/90 (91)
   n = 90 GMT, 95% CI (lower-upper) 12.86 (10.67-15.51) 40.90 (30.09-50.08)
Dose 2 Seropositive rate (%) 62/66 (93.9) 64/66 (97.0)
   n = 66 GMT, 95% CI (lower-upper) 33.05 (24.42-44.60) 213.84 (151.54-301.59)
PRNT50, plaque reduction neutralization test; GMT, geometric mean antibody titers; CI, confidential interval.
Table 2. Solicited and unsolicited adverse events reported during 0-42 days follow-
ing each dose
Adverse events Dose 1, n = 90 (%) Dose 2, n = 69 (%)
Solicited local
Redness
Swelling
Pain/Tenderness
12 (13.3)
7 (7.8)
8 (8.9)
17 (24.6)
8 (11.6)
14 (20.3)
Solicited systemic
Fever
Sleepiness
Irritability
Skin rash
4 (4.4)
1 (1.1)
0 (0)
2 (2.2)
5 (7.2)
3 (4.3)
2 (2.9)
2 (2.9)
Unsolicited
Nasopharyngitis
Rhinitis
Gastroenteritis
Skin rash
Conjunctivitis
Others
6 (6.7)
6 (6.7)
6 (6.7)
3 (3.3)
2 (2.2)
4 (4.4)
12 (17.4)
4 (5.8)
1 (1.5)
3 (4.5)
2 (2.9)
5 (7.2)
were calculated using a percentile-based bootstrap method 
stratified by baseline serostatus. The percentages of subjects 
who experienced solicited and unsolicited adverse reactions 
were expressed. Missing data were excluded. 
Ethics statement
This study was approved by the institutional review board of 
each study site (IRB number OCMC07MI020 and OCMC08MI 033). 
Written informed consent was obtained from the parents or le-
gal representative of all subjects before study enrollment.
RESULTS
Subjects
Ninety subjects were enrolled to receive the first dose vaccine 
at five study centers. The male to female ratio was 1.0, and the 
median age at enrollment was 12 ± 4 months (87 children age 
12-23 months, two 24-35 months, and one 36-47 months). There 
were no withdrawals due to adverse events after the first vacci-
nation. Among all subjects enrolled at the first vaccination, 19 
subjects were lost to follow up at the second vaccination and 2 
voluntarily withdrew participation. Overall, a total of 69 sub-
jects completed the following study, thus receiving the second 
dose. Three samples after the second dose were not included in 
the immunogenicity analysis for reasons expected to impact 
immunogenicity such as erroneous sampling or inappropriate 
sampling time, but these cases were not excluded from the safe-
ty analysis. The male to female ratio of the follow-up group was 
1.25, and the median age was 24 ± 4 months (67 children age 
24-35 months, one 36-47 months, and one 48-59 months).
Immunogenicity results
The immunogenicity results are summarized in Table 1. Sero-
protection to the first dose was observed in 91.1% (82/90) of sub-
jects. The GMT showed an increase of 3-fold (40.90, 95% CI, 30.09-
50.58), from 12.86 (95% CI, 10.67-15.51) at baseline. 
 At the 1-yr follow-up, 4 out of 66 subjects had no detectable 
neutralizing antibody. Overall, the seroprotection rate following 
the second dose rose to 97% (64/66), compared to 93.9% (62/66) 
prior to vaccination. The GMT was measured from 33.05 (95% 
CI, 24.42-44.60) to 213.84 (95% CI, 151.54-301.59), representing 
a 6.47-fold rise.
Safety 
The results of adverse reactions after each dose are summarized 
in Table 2. Adverse events reported by all subjects after the first 
dose were mild to moderate in severity and self-limited in dura-
tion, with 18.9% of subjects reporting one or more adverse events. 
The most frequently reported local reactions after the first dose 
were redness (13.3%) and tenderness (8.9%) at the injection site. 
Systemic reactions were infrequent with the exception of fever 
(4.4%), but no subject experienced a fever ≥ 40°C. During the 
42 days following vaccination, unsolicited adverse events were 
experienced by 30% of children. Most unsolicited adverse events 
were not related to vaccination, and included nasopharyngitis 
(6.7%), rhinitis (6.7%), gastroenteritis (6.7%), skin rash (3.3%), 
and conjunctivitis (2.2%). 
 The incidence of solicited local reactions was slightly higher 
after the second dose (30.3%) than the first dose. The most fre-
quently reported local reaction was redness and tenderness, 
which occurred in 24.6% and 20.3% of subjects, respectively. 
Fever was developed in 7.2% subjects after the second dose. 
There were no serious adverse events, deaths, or withdrawals 
from the study due to any type of adverse event. 
DISCUSSION
Over the past decades, there has been the geographical expan-
sion of JE to new territories, and recurrent outbreaks in Vietnam, 
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Nepal, and India (17). Because there is no other effective public 
health option for the prevention of JE, vaccination is the best 
tool for JE control. A number of organizations including PATH, 
WHO, UNICEF, and the United States CDC are together devel-
oping a strategic plan that could broadly control JE by 2015 (18). 
In the countries where high vaccination coverage has been achi-
eved, such as in Japan, Taiwan, Thailand, and Korea, the inci-
dence of JE has decreased, primarily as a result of widespread 
use of vaccines (17). The choice of vaccine will need to take into 
account long-term protection, ease of administration, cost, and 
above all, safety. 
 The primary outcome of this study was the remarkable im-
munogenicity of LAJEV given to Korean children aged 1 to 3 yr 
with local schedule. After the first dose, seroprotection was ob-
tained in about 90% of subjects and the GMT increased 3-fold. 
Protective levels of antibodies were maintained in 93.9% of the 
subjects until the time of administration of the second dose, 
which was given 1 yr later. This finding is similar to previously 
published studies with relatively high immunogenicity (19-23). 
However, the seroprotection rate in a few studies was higher 
compared to our results. In a case-control study in Nepal, one 
dose of the vaccine given to children and adolescents aged 1 to 
15 yr was shown to be 98.5% protective 1 yr following vaccina-
tion (24) and the vaccine remained protective at an estimated 
96% 5 yr after vaccination in JE-endemic areas (25). A clinical 
study conducted by Sohn et al. revealed that LAJEV given as a 
single dose to Korean children aged 1 to 3 yr (mean age 27 mon-
ths) produced seroprotection with antibody response as high 
as 96% (20), which possibly reflects the methodological differ-
ences in titer calculations, as noted by the authors (9, 19). In ad-
dition, age differences in the study groups may also affect anti-
body response. 
 The children enrolled in our study responded strongly to the 
second dose (96%), and the GMT increased by approximately 
6.5-fold from the first dose level. A schedule was introduced in 
Korea based on results of a field trial of more than 250,000 Chi-
nese children which found that high efficacy was achieved with 
two vaccine doses given 1 yr apart (13). Although the immuno-
genicity of two doses given 1 and 2.5 months apart has been re-
ported in children ranging from 12 to 15 yr old (19), studies of 
the principal target group for primary immunization have not 
previously been conducted. Our study highlights antibody re-
sponses in young children, who are the target group for primary 
immunization in Korea. The 2-dose schedule of LAJEV could 
help to immunize children who did not have an adequate re-
sponse to a first dose, and decrease the number of secondary 
vaccine failures. However, observational studies on children in 
China, Nepal and Thailand have suggested that even single dose 
of this vaccine can produce significant long-term protection 
(25, 26). Based on consideration of cost-benefit effect, there is a 
need for carefully planned studies to establish more optimal 
immunization schedule.
 In this study, LAJEV was safe and well-tolerated. Reactoge-
nicity was satisfactory, although local reactions tended to be 
more frequent after the second dose. The systemic reactions 
were mainly fever, which was seen in less than 10% of subjects 
during the study, and which resolved spontaneously in all cas-
es. Most adverse events were relatively mild and self-limiting. 
There were no reports of encephalitis or aseptic meningitis fol-
lowing vaccination. In a prospective, randomized study where 
patients were actively monitored for 30 days, no cases of enceph-
alitis or meningitis were observed, and no differences in hospi-
talization or prolonged fever were found (10). However, recent 
encephalitis cases have been reported in Chinese patients who 
received a first dose of LAJEV, although it is difficult to identify 
the causal link between the disease and JE vaccination (27). 
Therefore, concerns about safety still remain, and continued 
surveillance and careful investigation of any events that occur 
after LAJEV is required.
 Some limitations of our study must be considered. First, the 
number of study subjects were relatively small. However, the 
study design was prospective, and the serial assessment of im-
munogenicity and safety of LAJEV over 1 yr was firstly done in 
Korean children with local schedule. Second, it is necessary to 
observe the long-term safety of this vaccine. Although severe 
neurologic or hypersensitivity reactions did not occur during 
this study, the prolonged observation of adverse events is re-
quired. Third, we did not assess the interchangeability of other 
available JE vaccines. Because the national immunization pro-
gram (NIP) in Korea includes inactivated JE vaccine and LAJEV 
(approved as NIP vaccine in 2014), clinicians can face this situ-
ation considering interchangeable vaccination when a patient 
is lacking a vaccination record or there is a limited vaccine sup-
ply from a particular manufacturer. These limitations need to 
be addressed in future studies. 
 In conclusion, our findings provide evidence of high protec-
tion rate elicited by a 2-dose schedule of LAJEV given 1 yr apart. 
With respect to vaccine safety, there was no severe vaccine-re-
lated adverse events. Although the data is insufficient to con-
clude whether LAJEV can prevent JE outbreaks, we expect that 
this immunization strategy will decrease the susceptibility level 
and increase herd immunity in affected regions, and thereby 
substantially reduce the burden of JE.
DISCLOSURE
The authors have no conflicts of interest to disclose.
AUTHOR CONTRIBUTION
Conception and coordination of the study: Kang JH. Design of 
ethical issues: Lee SY, Kim KH, Kim DS, Cha SH, Jo DS, Kang 
Kwon HJ, et al. • Japanese Encephalitis Vaccine in Children
616  http://jkms.org http://dx.doi.org/10.3346/jkms.2015.30.5.612
JH. Acquisition of data: Lee SY, Kim KH, Kim DS, Cha SH, Jo DS, 
Kang JH. Data review: Kwon HJ, Kang JH. Statistical analysis: 
Kwon HJ, Kang JH, Manuscript preparation: Kwon HJ, Kang JH. 
Manuscripts approval: all authors.
ORCID
Hyo Jin Kwon http://orcid.org/0000-0001-5238-1931 
Soo Young Lee http://orcid.org/0000-0002-5354-3135
Ki Hwan Kim http://orcid.org/0000-0001-6145-3909
Dong Soo Kim http://orcid.org/0000-0002-3270-506X
Sung Ho Cha http://orcid.org/0000-0003-0540-5747
Dae Sun Jo http://orcid.org/0000-0002-3141-9539
Jin Han Kang http://orcid.org/0000-0003-1610-6742 
REFERENCES
1. Mackenzie JS, Johansen CA, Ritchie SA, van den Hurk AF, Hall RA. Jap-
anese encephalitis as an emerging virus: the emergence and spread of 
Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol 
2002; 267: 49-73.
2. Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF, 
Pyke AT, Johansen CA, Mackenzie JS. Japanese encephalitis in north 
Queensland, Australia, 1998. Med J Aust 1999; 170: 533-6.
3. Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese en-
cephalitis. Cochrane Database Syst Rev 2007: CD004263.
4. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev Vaccines 
2008; 7: 689-93.
5. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, In-
nis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, et al. Protec-
tion against Japanese encephalitis by inactivated vaccines. N Engl J Med 
1988; 319: 608-14.
6. Inactivated Japanese encephalitis virus vaccine. Recommendations of 
the Advisory Committee on Immunization Practices (ACIP). MMWR 
Recomm Rep 1993; 42: 1-15.
7. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese 
encephalitis vaccine. Expert Opin Biol Ther 2009; 9: 921-31.
8. Lindsey NP, Staples JE, Jones JF, Sejvar JJ, Griggs A, Iskander J, Miller 
ER, Fischer M. Adverse event reports following Japanese encephalitis 
vaccination in the United States, 1999-2009. Vaccine 2010; 29: 58-64.
9. Xin YY, Ming ZG, Peng GY, Jian A, Min LH. Safety of a live-attenuated 
Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop 
Med Hyg 1988; 39: 214-7.
10. Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC, Xiang CF, Bilk-
er WB, Pan XP, Yao YJ, et al. Short-term safety of live attenuated Japanese 
encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 
subjects. J Infect Dis 1997; 176: 1366-9.
11. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly 
Epidemiol Rec 2005; 80: 242-7.
12. Tsai TF. New initiatives for the control of Japanese encephalitis by vacci-
nation: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 Oc-
tober 1998. Vaccine 2000; 18: 1-25.
13. Solomon T. Japenese encephalitis vaccine. In: Jong EC, Juckerman JN, 
editor, Travelers’ vaccine. Hamilton, Ont: BC Decker, 2004, p219-56.
14. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction 
test for dengue virus neutralizing antibodies. J Immunol 1967; 99: 285-90.
15. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO 
consultation on immunological endpoints for evaluation of new Japa-
nese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 
2005; 23: 5205-11.
16. Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, Hansen J, 
Labadie J, Lee L, Martin BL, et al. Brighton Collaboration Fever Working 
Group, Fever as an adverse event following immunization: case defini-
tion and guidelines of data collection, analysis, and presentation. Vac-
cine 2004; 22: 551-6.
17. Yaïch M. Investing in vaccines for developing countries: how public-pri-
vate partnerships can confront neglected diseases. Hum Vaccin 2009; 5: 
368-9.
18. Halstead SB, Thomas SJ. Japanese encephalitis: new options for active 
immunization. Clin Infect Dis 2010; 50: 1155-64.
19. Tsai TF, Yu YX, Jia LL, Putvatana R, Zhang R, Wang S, Halstead SB. Im-
munogenicity of live attenuated SA14-14-2 Japanese encephalitis vac-
cine--a comparison of 1- and 3-month immunization schedules. J Infect 
Dis 1998; 177: 221-3.
20. Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF. Primary 
and booster immune responses to SA14-14-2 Japanese encephalitis vac-
cine in Korean infants. Vaccine 1999; 17: 2259-64.
21. Chotpitayasunondh T, Sohn YM, Yoksan S, Min J, Ohrr H. Immunizing 
children aged 9 to 15 months with live attenuated SA14-14-2 Japanese 
encephalitis vaccine in Thailand. J Med Assoc Thai 2011; 94: S195-203.
22. Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Ya-
ïch M, Jacobson J. Comparison of the immunogenicity and safety of mea-
sles vaccine administered alone or with live, attenuated Japanese enceph-
alitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008; 26: 2234-41.
23. Wijesinghe PR, Abeysinghe MR, Yoksan S, Yao Y, Zhou B, Zhang L, Yaich 
M, Neuzil KM, Victor JC. Safety and immunogenicity of live-attenuated 
Japanese encephalitis SA 14-14-2 vaccine co-administered with measles 
vaccine in 9-month-old infants in Sri Lanka. Vaccine 2014; 32: 4751-7.
24. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect 
of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepal-
ese children with Japanese encephalitis: a case-control study. Lancet 2005; 
366: 1375-8.
25. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB. 
Single dose of SA 14-14-2 vaccine provides long-term protection against 
Japanese encephalitis: a case-control study in Nepalese children 5 years 
after immunization. Vaccine 2007; 25: 5041-5.
26. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006; 81: 331-40.
27. Jia N, Zhao QM, Guo XF, Cheng JX, Wu C, Zuo SQ, Dai PF, Zhao JY, Zhang 
JS. Encephalitis temporally associated with live attenuated Japanese en-
cephalitis vaccine: four case reports. BMC Infect Dis 2011; 11: 344.
